LEIDEN, THE NETHERLANDS--(Marketwire - July 03, 2012) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that
signed an agreement to sell the tangible assets of its US operations.
the announcement of the closure of the US based cattle platform
operations, a swift process has lead to the sale of the tangible
farm buildings and surrounding land in Wisconsin, to Sexing
private company based in Navasota, Texas. Sexing Technologies Inc.
in the genetic improvement and reproductive services and export of
primarily through the production and commercialization of sexed sorted
embryos, around the globe (http://www.sexingtechnologies.com/). Please
our press release of 25 June 2012 for more details on the closing of
based research facilities.
Further discussions concerning the sale of some of the legacy projects that
primarily located in the US operation are ongoing.
About RUCONEST® and Hereditary Angioedema
RUCONEST® (INN conestat alfa) is a recombinant version of the human
inhibitor (C1INH). RUCONEST is produced through Pharming's
technology in milk of transgenic rabbits and is approved in Europe for
of acute angioedema attacks in patients with HAE. RUCONEST®
investigational drug in the U.S. and has been granted orphan drug
for the treatment of acute attacks of HAE, a genetic disorder in
patient is deficient in or lacks a functional plasma protein C1
resulting in unpredictable and debilitating episodes of intense swelling
extremities, face, trunk, genitals, abdomen and upper airway. The
severity of HAE attacks vary and are most serious when they involve
edema, which can close the upper airway and cause death by
According to the U.S. Hereditary Angioedema Association,
estimates for HAE range from one in 10,000 to one in 50,000 individuals.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
medical needs. RUCONEST® is a recombinant human C1 inhibitor
approved for the
treatment of angioedema attacks in patients with HAE in all 27 EU countries
Norway, Iceland and Liechtenstein, and is distributed in the EU by
Orphan Biovitrum (OMX: SOBI). RUCONEST® is partnered with
(NASDAQ: SNTS) in North America where the drug is undergoing Phase III
development. The product is also being evaluated for follow-on
the areas of transplantation and reperfusion injury. The advanced
of the Company include innovative and validated platforms for the
protein therapeutics, technology and processes for the purification
formulation of these products. A feasibility study, using the
transgenic rabbit platform, aimed at the development of recombinant Factor
for the treatment of Haemophilia A is underway with partner, Renova Life,
Additional information is available on the Pharming website,
To download the Pharming Group Investor Relations App, click here.
This press release contains forward looking statements that involve
unknown risks, uncertainties and other factors, which may cause the
results, performance or achievements of the Company to be materially
from the results, performance or achievements expressed or implied by
forward looking statements.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE